Last reviewed · How we verify
BNT162b5 Bivalent (WT/OMI BA.2) (bnt162b5-bivalent-wt-omi-ba-2)
Pfizer's BNT162b5 Bivalent (WT/OMI BA.2) is a marketed COVID-19 vaccine for individuals 12 years and older. It is a bivalent vaccine, meaning it targets two different variants of the virus. The vaccine has generated $21.2B in revenue. Its key indications include COVID-19 prevention and treatment. The vaccine's clinical differentiation lies in its ability to target multiple variants of the virus. Commercially, it is a significant product for Pfizer. There are no pipeline developments mentioned.
At a glance
| Generic name | bnt162b5-bivalent-wt-omi-ba-2 |
|---|---|
| Sponsor | Pfizer |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention in individuals 12 years of age and older
- COVID-19 treatment in individuals 12 years of age and older
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- CYP3A4 inducers
- CYP3A4 inhibitors
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP1A2 inducers
- CYP1A2 inhibitors
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2C9 inhibitors
Key clinical trials
- A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b5 Bivalent (WT/OMI BA.2) CI brief — competitive landscape report
- BNT162b5 Bivalent (WT/OMI BA.2) updates RSS · CI watch RSS
- Pfizer portfolio CI